Psychedelic Progress: LSD-Derived M-120 Fast-Tracked for Generalized Anxiety Disorder Treatment

Dr. Tracey Marks discusses the significant advancement in psychedelic medicine with the FDA granting breakthrough therapy status to Mind Medicine's M-120, a drug derived from LSD, for the treatment of generalized anxiety disorder (GAD). A Phase 2 trial demonstrated a robust reduction in anxiety symptoms starting by day two, with improvements lasting at least 12 weeks after a single dose. This designation accelerates the drug's development and approval process, highlighting a potential paradigm shift in mental health treatment.

The podcast delves into the proposed mechanisms of action for psychedelics like M-120, distinguishing them from traditional psychiatric medications. Instead of merely replenishing brain chemicals, these compounds are believed to work at a 'rewiring level.' Key mechanisms include enhancing neuroplasticity, the brain's ability to form new neural connections, which allows for changes in thought patterns and emotional processing. Another mechanism involves modulating the default mode network (DMN), the brain region responsible for generating background thoughts and inner monologue. Psychedelics are thought to 'turn down the volume' or 'wipe clean' negative thought loops associated with anxiety and depression, enabling individuals to reprogram their thoughts on a clean slate.

Dr. Marks outlines the lengthy FDA approval process, from discovery and preclinical research to investigational new drug (IND) applications and three phases of clinical trials, culminating in a new drug application (NDA). She provides updates on other psychedelic compounds, noting that MDMA for PTSD (developed by Lycos Therapeutics, formerly MAPS) is expected to be the first of this new wave to reach the market, with psilocybin for depression (Compass Pathways) also in advanced trials. Ketamine is acknowledged as the first psychedelic already in clinical practice.

Finally, the episode addresses potential skepticism by offering natural alternatives for enhancing neuroplasticity and brain function. These include physical exercise, meditation and mindfulness, omega-3 fatty acids, curcumin, flavonoids (found in dark chocolate, blueberries, green tea), deep sleep, socialization, new experiences, and intermittent fasting. Many of these interventions work by activating brain-derived neurotrophic factor (BDNF), a protein that promotes nerve growth and connection. While these natural options don't replicate the psychedelic experience, they offer sustainable, long-term benefits for mental well-being, underscoring a holistic approach to brain health.

The FDA granted breakthrough status on a new product.

Their latest phase two trial showed that one dose of M1 20 showed robust reduction in anxiety symptoms, starting by day two, and that improvement lasted for at least 12 weeks from that single dose.

Psychedelic compounds caused dissociative and reality altering experiences when they are consumed.

One is through enhanced neuroplasticity, which is the brain's ability to form new neural connections.

Another possible mechanism is changing the activity of your default mode network.

Psychedelics are thought to either turn down the volume really low on this tape or wipe it clean altogether, allowing you to reprogram your thoughts.

They work at the rewiring level and not at the replenished brain chemicals level.

MDMA will be the first of this group to make it to market, and the second psychedelic used in clinical practice. Ketamine is the first one.

Bdnf is a protein that works like fertilizer in the brain. It helps nerves grow and connect to each other, and helps prune bad nerve connections.

Although these options don't replicate the psychedelic experience, they can offer sustainable, long term benefits to brain function and mental well-being.